Combining inhibitors of AKR1C3, glutathione synthesis, and/or proteasomal proteolysis has proven effective in enhancing cisplatin sensitivity in breast cancer cells (Kobayashi et al., 2022). This evidence concerns the gene AKR1C3 and breast carcinoma.